Evidence map›Paper›PMID 29403289›Full record

ArticleOncoTargets and therapy2018

Association of clinicopathologic characteristics and outcomes with

Farnaz Boostani, Roya Dolatkhah, Ashraf Fakhrjou, Faris Farassati, Zohreh Sanaat

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Farnaz BoostaniHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Roya DolatkhahHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ashraf FakhrjouTabriz University of Medical Sciences, Tabriz, Iran.
Faris FarassatiMidwest Biomedical Research Foundation, Kansas City, MO, USA.
Zohreh SanaatHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRBiomedical Research Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, it was found that the overexpression and mutation status of

methodsThis was an analytical descriptive study of surgical specimens of primary breast tumors. Specimens were analyzed immunohistochemically for

resultsWe included 100 patients with breast cancer (mean age 51.05±9.54 years). The multivariate regression analysis showed that HER2-positive patients had approximately twice the levels of

conclusionThere was no association found between

Indexed as

breast cancerenhancer of zeste homolog 2 proteinsurvival analysistumor markers

Identifiers

PMID29403289
PMCPMC5783027
OpenAlexW2782646490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.